Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.

Abstract

We investigated the changes in serum lipid concentrations of patients treated with Etofibrate as part of their routine management in the metabolic ambulatory care unit of the Medical Policlinic at the University of Marburg. In our study, 26 patients who had not responded well to prior treatment for Types IIa, IIb, III and IV hyperlipoproteinemia were given a daily dose of 900 mg Etofibrate for up to 48 months. As a result to this treatment, serum total cholesterol levels fell by up to 17,6% and triglyceride levels by up to 47,8%. We observed no tachyphylaxis toward Etofibrate. The results of standard laboratory parameters measured in parallel with drug treatment reflect a good tolerance for Etofibrate. This substance is highly suited as a potent lipid-lowering agent.

• Authors: H Kaffarnik, J Schneider, R Schubotz, P Zöfel, L Hausmann, K M Goebel
• Journal: Artery (Artery) Vol. 8 Issue 6 Pg. 537-46 ( 1980) ISSN: 0098-6127 [Print] United States
• PMID: 6114725 (Publication Type: Journal Article)

Chemical References

• Triglycerides
• etofibrate
• Uric Acid
• Clofibric Acid
• Cholesterol
• gamma-Glutamyltransferase
• Creatine Kinase
• Clofibrate

Topics

• Adult
• Aged
• Cholesterol (blood)
• Clofibrate (analogs & derivatives)
• Clofibric Acid (analogs & derivatives, therapeutic use)
• Creatine Kinase (blood)
• Female
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Hyperlipoproteinemia Type III (drug therapy)
• Hyperlipoproteinemia Type IV (drug therapy)
• Hyperlipoproteinemias (diet therapy, drug therapy)
• Long-Term Care
• Male
• Middle Aged
• Triglycerides (blood)
• Uric Acid (blood)
• gamma-Glutamyltransferase (blood)